Efficiently Target & Transduce Muscle Cells to Reduce Toxicity Risk, Increase Efficacy, & Administer High Dose Systemic Genetic Therapies Safely

The past twelve months have seen an unprecedented level of excitement, investment, and progression within the gene therapy for muscular disorders field. As the industry endeavours to move gene therapy treatment through the preclinical and clinical pipeline, in context of reducing toxicity and increasing efficacy, attending the 3rd Annual Gene Therapy for Muscular Disorders Summit has never been so crucial.

This year’s summit will return to Boston to reunite 100+ leading experts in biotech, pharma and academia to continue to develop strategies to deliver safer and more effective gene therapies to muscle cells.

This summit will encompass all aspects of preclinical development and highlight the obstacles in clinical trials, enabling you to address and overcome these challenges.

2023 Expert Speaker Faculty Includes

Adam Cockrell

Senior Director of Vector Biology

AavantiBio

Alex Murphy

Senior Medical Director

Roche

Kathy Ivey

VP Gene Therapy Research

Tenaya Therapeutics

Nicolas Christoforou

Rare Cardiac and Neuromuscular Disorders, Rare Disease Research Unit

Pfizer

Serge Braun

Director - Scientific & Neuromuscular Strategy

Genethon

Screenshot 2022-11-10 122216

"A well-organized intimate and focused meeting with key leaders discussing their clinical experiences and future designs to improve safety and performance" - Kriya Therapeutics

2023 Partners

download
CYTOO-Logo
Curi-Bio-Logo_full-color-for-light-bgs_no-space (002)

Other Events In The Gene Therapy Series: